News

DEDHAM, Mass., March 10, 2026 – Qlaris Bio, Inc., (“Qlaris”), a clinical-stage biotechnology company developing first-in-class therapies for glaucoma, today announced the appointment of Fred Guerard, Pharm.D., as president and chief executive officer (CEO), effective March 1, 2026. He will also join the company’s Board of Directors. Dr. Guerard brings more than two decades of […]

Experienced life sciences executive brings strategic and leadership expertise to support Qlaris Bio’s next phase of growth DEDHAM, Mass.–(BUSINESS WIRE)–Qlaris Bio, Inc., a clinical-stage biotechnology company focused on developing first-in-class therapies for glaucoma, today announced the appointment of Robert Warner to its board of directors. Mr. Warner’s appointment comes at a key time for Qlaris […]

Third study in Phase II program expands global clinical development of QLS-111 in patients with no previously approved treatment options Study to be conducted in South Korea where there is a high prevalence of Normal Tension Glaucoma DEDHAM, Mass. — [August 26, 2025] — Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in […]

QLS-111’s novel intraocular pressure-lowering mechanism targeting EVP to be highlighted in an oral presentation and two poster presentations DEDHAM, Mass. — June 23, 2025 — Qlaris Bio, Inc., a clinical‐stage biotechnology company dedicated to developing first‐in‐class therapies for glaucoma, today announced that new data from studies of its lead investigational compound QLS-111 will be presented […]

Combination therapy seeks to improve intraocular pressure lowering by pairing a novel EVP-targeting agent with prostaglandin analogue standard of care DEDHAM, Mass. — June 11, 2025 — Qlaris Bio, Inc., a clinical-stage biotechnology company, today announced that it is developing a novel preservative-free, fixed-dose combination (FDC) therapy that combines the company’s lead program, QLS-111, and […]